In 2013, seven friends from a Mumbai commerce college set out to build a business around a plant that Indian law still treats, in most forms, as a narcotic. Thirteen years on, Bombay Hemp Company — everyone calls it BOHECO — counts Ratan Tata among its backers, runs doctor-led cannabis wellness clinics in two metros, and yet still books under ₹10 crore in annual revenue.
That gap between symbolic weight and financial size is the whole story. BOHECO helped write India’s first state hemp policy, put cannabis research on the desk of the Council of Scientific and Industrial Research, and turned a stigma-heavy crop into a shelf of pain-relief tinctures. What it has not yet done, on the public record, is turn any of that into scale. This deep dive works through what BOHECO sells, who paid for the journey, and why a company with this much goodwill still earns so little.
Quick facts
| Company | Bombay Hemp Company Private Limited (BOHECO); CIN U74900MH2013PTC239878, registered in Mumbai, Maharashtra (ZaubaCorp/Tofler) |
| Founded | Incorporated 19 January 2013 under the Companies Act, 1956 (Tofler) |
| Founder(s) | Seven co-founders: Avnish Pandya, Jahan Peston Jamas, Sanvar Oberoi, Yash Kotak, Sumit Shah, Chirag Tekchandaney, Delzaad Deolaliwala (Forbes India) |
| Businesses | Hemp- and cannabis-derived wellness products (BOHECO Life), CBD oils/tinctures/capsules/topicals, Ayurvedic Vijaya formulations, doctor-led clinics and stores, R&D and contract research |
| Latest FY revenue | Under ₹10 crore for the year to 31 March 2025 (Tracxn); operating revenue placed in the ₹1–100 crore band for FY24 (ZaubaCorp/Tofler) |
| Latest FY profit/loss | Net profit margin reported at 26.8% and return on equity at 24.8% around FY24 (Tofler); absolute rupee figures sit behind paid MCA databases |
| Listed | Private; not listed on any exchange |
| Last valuation | Reported at about ₹94 crore as of January 2026 (Tracxn, single-source estimate) |
| Key shareholders / CEO | CEO Chirag Tekchandaney; backers include Ratan Tata and Rajan Anandan (Business Standard); directors on record: Jahan Peston Jamas and Chirag Tekchandaney (ZaubaCorp) |
What BOHECO does
BOHECO sells hemp and cannabis as health, not as a high. The company researches, formulates and retails wellness products derived from the cannabis plant, aimed at consumers managing pain, sleep, stress and inflammation, and it does this through a mix of e-commerce, physical stores and doctor-led clinics. Its consumer brand is BOHECO Life.
- Cannabinoid and CBD formats: oils, tinctures, capsules, gummies and topicals (Tracxn, company site).
- Flagship products Glide and Glide Plus, positioned for arthritis and joint pain (ItsHemp).
- Ayurvedic Vijaya (cannabis-leaf) formulations addressing pain, sleep, stress and neurological complaints (BioSpectrum).
- Doctor-led CBD clinics and stores in Delhi and Bengaluru, plus a network of virtual clinics (Indian Retailer, BioSpectrum).
The origin
The founding insight arrived on a road trip. In 2010, co-founder Jahan Peston Jamas travelled through Western Australia and saw the hemp industry around Margaret River operating in the open — hemp as food, as fibre, as medicine. As he later put it to Forbes India, the realisation that “everything from food to medicine to clothing can be made from it was the clincher.” He brought the idea back to a group of friends from HR College in South Mumbai, most of whom had graduated in 2011.
They did not quit their day jobs at once. The group researched industrial hemp on the side, then incorporated Bombay Hemp Company on 19 January 2013, dividing the work by aptitude: Pandya took R&D, Jamas strategy, Oberoi finance and technology, Kotak business development, Shah operations, Tekchandaney marketing and people, and Deolaliwala legal and accounts. The pitch was deliberately unromantic — hemp as an agricultural and industrial crop, a rotation option for farmers, not a gateway to anything. In a country where the plant carries a criminal shadow, that framing was the only way in.
The struggle years
The obstacle was written into law. The Narcotic Drugs and Psychotropic Substances Act of 1985 criminalises the resin and flowering tops of cannabis, with sentences that can reach two decades. Industrial hemp — the low-intoxicant cousin — sat in a grey zone that no bureaucrat wanted to touch. BOHECO’s early years were less about selling product and more about arguing a case.
- Founders “went knocking on doors of bureaucrats,” in Yash Kotak’s phrase, carrying hemp samples as physical proof that the crop was a solution, not a problem (Forbes India).
- The company lobbied to reinterpret and work within the NDPS Act rather than around it, pushing for a legal cultivation framework (Forbes India, Business Standard).
- That advocacy fed into Uttarakhand becoming the first Indian state to draft an industrial hemp policy, with early cultivation licences confined to Uttarakhand and Uttar Pradesh (company site, Business Standard).
- An early bet on hemp textiles stayed tiny: the textile line had generated only about ₹30 lakh since inception as of 2017, and roughly a quarter of the first big funding round was earmarked for it (Forbes India).
The near-death risk here was not a cash crunch so much as irrelevance: a fibre-and-fabric business in a market with almost no supply chain, no consumer demand and a hostile legal backdrop. The pivot that saved the story was a move away from clothing and towards medicine.
The turning point
The turning point was scientific credibility, and it had a date. In 2015–16, BOHECO set up an innovation lab with the Council of Scientific and Industrial Research (CSIR) and the National Botanical Research Institute (NBRI) at NBRI’s campus in Lucknow, working on seed cross-breeding and, later, on cannabis compounds for conditions such as epilepsy and chemotherapy side-effects (YourStory, BioSpectrum). A commerce-college startup was suddenly co-authoring research with a national laboratory.
The numbers on either side of that shift tell the tale. Before it, BOHECO was a small fibre venture. After it — and the medical-research halo it created — the company closed a seed round of ₹6.25 crore ($0.65 million) in December 2017 from Ratan Tata and former Google India managing director Rajan Anandan, among others (Business Standard, entrackr). Marquee capital validated the pivot from textiles to therapeutics, and set BOHECO on the path to the BOHECO Life wellness brand it runs today.
The money behind it
BOHECO’s cap table is unusually decorated for a company of its revenue. The funding shape, oldest to newest, on the public record:
- Seed, December 2017 — ₹6.25 crore: from Ratan Tata (Chairman Emeritus, Tata Sons) and Rajan Anandan, then Google India MD (Business Standard, entrackr).
- Follow-on, April 2018 — ₹3 crore: from Hong Kong textile firm Ginni International and existing investor Mukhtar Tejani of Gits Food (entrackr).
- Pre-Series A — $0.75 million: from Arphi Electronics, an AngelList Trust syndicate linked to an IIM-Kozhikode alumni fund, and Prakhar Agarwal of Adept Ventures (Trade Brains, The Week).
- Series A, November 2021 — about $2 million (~₹15 crore): from the family offices of Achin Kochar of the Vi-John Group and of Riteesh and Raghav Mohan Bakshi; reported at the time as the largest disclosed investment in India’s hemp industry (YourStory, The Week).
Totals are contested. In 2021 the company’s cumulative raise was reported at roughly $5.1 million (YourStory). Data platform Tracxn puts lifetime funding higher, at about $9.95 million across 11 rounds from 35 investors as of 2026, and pegs a valuation near ₹94 crore in January 2026 — both single-source estimates that BOHECO has not publicly confirmed, so treat them as reported rather than audited.
How it makes money
BOHECO earns as a branded consumer-health company sitting on top of its own research and manufacturing. The money flows and cost centres, as described across company and press sources:
- Product sales: BOHECO Life formulations sold direct through its website, third-party marketplaces and offline stores — the core revenue line.
- Clinics and consultations: doctor-led clinics and virtual consultations that both generate service revenue and channel prescriptions toward BOHECO products (Indian Retailer, BioSpectrum).
- Vertical integration: in-house R&D and manufacturing, so margin is captured from formulation through to retail rather than shared with contract makers (BioSpectrum).
- Costs out: clinical research and trials, regulatory and licensing work, brand building, customer acquisition and omnichannel distribution — the 2021 Series A was earmarked precisely for manufacturing, quality control, e-commerce and sales (The Week).
The part people get wrong: BOHECO is not a recreational cannabis play and cannot be. Its addressable market is legal, low-intoxicant, doctor-mediated wellness — a slower, evidence-gated business than the “cannabis boom” headlines imply.
The numbers
Absolute audited figures for recent years are held behind paid MCA-data subscriptions; what is on the open record is a mix of one clean early data point and later ranges and ratios. Unit is ₹ crore unless stated.
| Period | Revenue (₹ crore) | Profit / loss | Source |
| FY2017 | ~1.0 (with 5,060 customers, 18 staff) | Not disclosed | Forbes India |
| FY2024 | Operating revenue in the 1–100 band | Net profit margin ~26.8%; ROE ~24.8% | ZaubaCorp / Tofler |
| FY2025 | Under 10 | Not disclosed; ~1-year revenue CAGR ~37% | Tracxn |
- FY2017: about ₹1 crore in revenue from 5,060 customers with 18 employees; the textile sub-line was only ~₹30 lakh cumulatively (Forbes India).
- Around FY24, Tofler reported total revenue growth of roughly 44.5% year on year, net worth up about 84.4%, a net profit margin near 26.8% and return on equity near 24.8% — ratios that suggest a small but profitable base.
- FY25 revenue remained under ₹10 crore per Tracxn, which is the central tension: strong percentage growth on a very small absolute number.
- Headcount was around 41 as of February 2025 (Tracxn).
Where the money comes from
BOHECO’s revenue mix has shifted decisively from the crop to the clinic. The channel and segment split, as far as it is disclosed:
- Wellness products over textiles: the original industrial-hemp fibre and fabric business stayed marginal (~₹30 lakh cumulative by 2017), while cannabinoid and Ayurvedic wellness products became the growth engine (Forbes India).
- Omnichannel retail: sales run through the BOHECO website, external marketplaces and physical stores, with the doctor-clinic channel feeding demand (Indian Retailer).
- Geographic concentration: cultivation licences historically limited to Uttarakhand and Uttar Pradesh, while flagship clinics sit in Delhi and Bengaluru — supply and retail are geographically narrow (Business Standard, BioSpectrum).
The surprise: the “hemp company” barely sells hemp textiles. The economics were carried by cannabinoid wellness formulations and, increasingly, by clinical services — the November 2025 Bengaluru launch, billed as India’s largest cannabis-leaf-based wellness clinic and store and run with partner Soulgoal Artisan, is the clearest sign of that direction (BioSpectrum).
The risks
- Regulation is the whole ballgame. The NDPS Act, 1985 governs everything BOHECO touches, and cultivation permissions are granted state by state. A tightening at the Centre, or a state pulling licences, could cut off supply or product categories overnight; the compliance burden of keeping THC within legal limits is permanent.
- Evidence gap. BOHECO’s positioning depends on clinical credibility, but cannabis medicine in India is early. Trials with partners such as CSIR-NBRI, the National Institute of Ayurveda and Tata Memorial Centre take years, and until results land, marketing claims and reimbursement remain constrained (BioSpectrum).
- Scale versus story. Revenue under ₹10 crore after 13 years and multiple funding rounds means the model has not yet proven it can grow quickly. Percentage growth on a tiny base is easy; getting to a durable, large revenue line is the unsolved problem.
- Competition and stigma. Rivals such as Awshad and Hemp Horizons chase the same wellness consumer, while persistent public stigma raises the cost of educating buyers and clinicians alike.
The takeaway
BOHECO’s transferable lesson is about sequencing in a hostile market: when you cannot sell the product, sell the legitimacy first. The founders spent years building policy and scientific credibility — a state hemp policy, a CSIR lab, a Ratan Tata cheque — before the consumer business could exist at all. That groundwork is real and hard to copy. The unfinished half of the lesson is that legitimacy is not the same as scale. Thirteen years in, BOHECO has arguably done more than anyone to make cannabis wellness respectable in India, and still has to prove it can turn that respect into revenue.
Frequently asked questions
What is BOHECO and what does it sell?
Bombay Hemp Company (BOHECO) is a Mumbai-registered company founded in 2013 that researches and sells hemp- and cannabis-derived wellness products under the BOHECO Life brand, including CBD oils, tinctures, capsules and topicals, alongside doctor-led clinics.
Who are BOHECO’s investors?
Backers include Ratan Tata and former Google India MD Rajan Anandan, who joined a December 2017 seed round of ₹6.25 crore, plus later investors such as Ginni International, the Vi-John Group’s Achin Kochar and the Mohan Bakshi family (Business Standard, entrackr, The Week).
Is BOHECO profitable?
Around FY24, Tofler reported a net profit margin near 26.8% and return on equity near 24.8%, suggesting profitability on a small base, though absolute audited figures are not public and FY25 revenue remained under ₹10 crore (Tracxn).
Is cannabis legal in India, and how does BOHECO operate?
The NDPS Act, 1985 criminalises cannabis resin and flowering tops, but low-intoxicant industrial hemp and certain Ayurvedic cannabis-leaf (Vijaya) uses are permitted within state-licensed frameworks; BOHECO works inside those rules, with cultivation historically licensed in Uttarakhand and Uttar Pradesh.
How much money has BOHECO raised?
Cumulative funding was reported at about $5.1 million in 2021; the data platform Tracxn estimates roughly $9.95 million across 11 rounds by 2026, a figure BOHECO has not publicly confirmed.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Forbes India, “On the hemp trail: Boheco’s attempt to build a new narrative around cannabis” (founding story, FY2017 revenue) — 2018.
- Business Standard, “Ratan Tata, Rajan Anandan invests in cannabis research firm Boheco” — December 2017.
- entrackr, “Ratan Tata-backed cannabis research Boheco raises fresh capital” (seed and April 2018 round) — April 2018.
- YourStory, “Ratan Tata-backed startup Bombay Hemp raises $2M” (Series A, total raised) — November 2021.
- The Week / PTI wire, “Ratan Tata-backed Bombay Hemp Company raises largest reported investment in the hemp industry in India” — November 2021.
- Trade Brains, “Bombay Hemp Company” feature (funding detail) — November 2021.
- BioSpectrum India, “BOHECO opens India’s largest cannabis leaf-based wellness clinic in Bengaluru” (products, clinics, research partners) — November 2025.
- Indian Retailer, “How BOHECO is revolutionizing health & wellness with CBD clinic and store” — 2024.
- ZaubaCorp and Tofler, Bombay Hemp Company Private Limited (CIN U74900MH2013PTC239878) corporate and financial records — accessed September 2026.
- Tracxn, BOHECO company profile (funding, valuation, revenue band, headcount) — accessed September 2026.
- Trading Economics, USD/INR reference rate — 18 September 2026.
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.